FOXA1 in breast cancer

Harikrishna Nakshatri; Sunil Badve

doi:10.1017/S1462399409001008

FOXA1 in breast cancer

Published online by Cambridge University Press: 05 March 2009

Harikrishna Nakshatri and

Sunil Badve

Show author details

Harikrishna Nakshatri*: Affiliation:
Departments of Surgery, Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Sunil Badve: Affiliation:
Department of Pathology and Internal Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
*: *Corresponding author: Harikrishna Nakshatri, R4-202, Indiana University School of Medicine, 1044 West Walnut Street, Indianapolis, IN 46202, USA. Tel: +1 317 278 2238; Fax: +1 317 274 0396; E-mail: [email protected]

Article contents

Abstract
References

Get access

Rights & Permissions

Abstract

Breast cancer is a heterogeneous disease and classification is important for clinical management. At least five subtypes can be identified based on unique gene expression patterns; this subtype classification is distinct from the histopathological classification. The transcription factor network(s) required for the specific gene expression signature in each of these subtypes is currently being elucidated. The transcription factor network composed of the oestrogen (estrogen) receptor α (ERα), FOXA1 and GATA3 may control the gene expression pattern in luminal subtype A breast cancers. Breast cancers that are dependent on this network correspond to well-differentiated and hormone-therapy-responsive tumours with good prognosis. In this review, we discuss the interplay between these transcription factors with a particular emphasis on FOXA1 structure and function, and its ability to control ERα function. Additionally, we discuss modulators of FOXA1 function, ERα–FOXA1–GATA3 downstream targets, and potential therapeutic agents that may increase differentiation through FOXA1.

Type: Review Article
Information: Expert Reviews in Molecular Medicine , Volume 11 , July 2009 , e8

DOI: https://doi.org/10.1017/S1462399409001008 [Opens in a new window]
Copyright: Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Visvader, J.E. and Lindeman, G.J. (2006) Mammary stem cells and mammopoiesis. Cancer Research 66, 9798-9801CrossRef Google Scholar PubMed

2Raouf, A. et al. (2008) Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell 3, 109-118CrossRef Google Scholar PubMed

3Villadsen, R. (2005) In search of a stem cell hierarchy in the human breast and its relevance to breast cancer evolution. APMIS 113, 903-921CrossRef Google Scholar PubMed

4Carroll, J.S. et al. (2005) Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122, 33-43CrossRef Google Scholar PubMed

5Laganiere, J. et al. (2005) From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proceedings of the National Academy of Sciences of the United States of America 102, 11651-11656CrossRef Google Scholar PubMed

6Eeckhoute, J. et al. (2007) Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Research 67, 6477-6483CrossRef Google Scholar PubMed

7Costa, R.H., Grayson, D.R. and Darnell, J.E. Jr (1989) Multiple hepatocyte-enriched nuclear factors function in the regulation of transthyretin and alpha 1-antitrypsin genes. Molecular and Cellular Biology 9, 1415-1425Google Scholar PubMed

8Lai, E. et al. (1990) HNF-3A, a hepatocyte-enriched transcription factor of novel structure is regulated transcriptionally. Genes and Development 4, 1427-1436CrossRef Google Scholar PubMed

9Lai, E. et al. (1991) Hepatocyte nuclear factor 3 alpha belongs to a gene family in mammals that is homologous to the Drosophila homeotic gene fork head. Genes and Development 5, 416-427CrossRef Google Scholar

10Kaestner, K.H. (2000) The hepatocyte nuclear factor 3 (HNF3 or FOXA) family in metabolism. Trends in Endocrinology and Metabolism 11, 281-285CrossRef Google Scholar PubMed

11Matusik, R.J. et al. (2008) Prostate epithelial cell fate. Differentiation 76, 682-698CrossRef Google Scholar PubMed

12Panowski, S.H. et al. (2007) PHA-4/Foxa mediates diet-restriction-induced longevity of C. elegans. Nature 447, 550-555CrossRef Google Scholar PubMed

13Cirillo, L.A. et al. (2002) Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Molecular Cell 9, 279-289CrossRef Google Scholar PubMed

14Clark, K.L. et al. (1993) Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature 364, 412-420CrossRef Google Scholar PubMed

15Cirillo, L.A. and Zaret, K.S. (2007) Specific interactions of the wing domains of FOXA1 transcription factor with DNA. Journal of Molecular Biology 366, 720-724CrossRef Google Scholar PubMed

16Qian, X. and Costa, R.H. (1995) Analysis of hepatocyte nuclear factor-3 beta protein domains required for transcriptional activation and nuclear targeting. Nucleic Acids Research 23, 1184-1191CrossRef Google Scholar PubMed

17Achatz, G. et al. (1997) Functional domains of the human orphan receptor ARP-1/COUP-TFII involved in active repression and transrepression. Molecular and Cellular Biology 17, 4914-4932CrossRef Google Scholar PubMed

18Kim, J.Y. et al. (2004) Orphan nuclear receptor small heterodimer partner represses hepatocyte nuclear factor 3/Foxa transactivation via inhibition of its DNA binding. Molecular Endocrinology 18, 2880-2894CrossRef Google Scholar PubMed

19Gao, N. et al. (2003) The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Molecular Endocrinology 17, 1484-1507CrossRef Google Scholar PubMed

20Minoo, P. et al. (2007) Physical and functional interactions between homeodomain NKX2.1 and winged helix/forkhead FOXA1 in lung epithelial cells. Molecular and Cellular Biology 27, 2155-2165CrossRef Google Scholar PubMed

21Minoo, P. et al. (2008) SMAD3 prevents binding of NKX2.1 and FOXA1 to the SpB promoter through its MH1 and MH2 domains. Nucleic Acids Research 36, 179-188CrossRef Google Scholar

22Sekiya, T. and Zaret, K.S. (2007) Repression by Groucho/TLE/Grg proteins: genomic site recruitment generates compacted chromatin in vitro and impairs activator binding in vivo. Molecular Cell 28, 291-303CrossRef Google Scholar PubMed

23Kouzarides, T. (2007) Chromatin modifications and their function. Cell 128, 693-705CrossRef Google Scholar PubMed

24Lupien, M. et al. (2008) FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132, 958-970CrossRef Google Scholar PubMed

25Li, B., Carey, M. and Workman, J.L. (2007) The role of chromatin during transcription. Cell 128, 707-719CrossRef Google Scholar PubMed

26Klose, R.J. et al. (2007) The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell 128, 889-900CrossRef Google Scholar PubMed

27Christensen, J. et al. (2007) RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell 128, 1063-1076CrossRef Google Scholar PubMed

28Iwase, S. et al. (2007) The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell 128, 1077-1088CrossRef Google Scholar PubMed

29Yamane, K. et al. (2007) PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Molecular Cell 25, 801-812CrossRef Google Scholar PubMed

30Kouros-Mehr, H. et al. (2006) GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127, 1041-1055CrossRef Google Scholar PubMed

31Asselin-Labat, M.L. et al. (2007) Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nature Cell Biology 9, 201-209CrossRef Google Scholar PubMed

32Badve, S. et al. (2007) FOXA1 expression in breast cancer correlation with luminal subtype A and survival. Clinical Cancer Research 13, 4415-4421CrossRef Google Scholar PubMed

33Clarke, R.B. et al. (1997) Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Research 57, 4987-4991Google Scholar PubMed

34Varley, C.L. et al. (2008) FOXA1 and IRF-1 intermediary transcriptional regulators of PPARgamma-induced urothelial cytodifferentiation. Cell Death and Differentiation 16, 103-114CrossRef Google Scholar PubMed

35Jacob, A., Budhiraja, S. and Reichel, R.R. (1999) The HNF-3alpha transcription factor is a primary target for retinoic acid action. Experimental Cell Research 250, 1-9CrossRef Google Scholar PubMed

36Doane, A.S. et al. (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25, 3994-4008CrossRef Google Scholar PubMed

37Naderi, A. and Hughes-Davies, L. (2008) A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 10, 542-548CrossRef Google Scholar PubMed

38Sinner, D. et al. (2004) Sox17 and beta-catenin cooperate to regulate the transcription of endodermal genes. Development 131, 3069-3080CrossRef Google Scholar PubMed

39Schuettengruber, B. et al. (2007) Genome regulation by polycomb and trithorax proteins. Cell 128, 735-745CrossRef Google Scholar PubMed

40Bracken, A.P. et al. (2006) Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes and Development 20, 1123-1136CrossRef Google Scholar PubMed

41Lee, T.I. et al. (2006) Control of developmental regulators by polycomb in human embryonic stem cells. Cell 125, 301-313CrossRef Google Scholar PubMed

42Schneider, J. et al. (2006) Identification and meta-analysis of a small gene expression signature for the diagnosis of estrogen receptor status in invasive ductal breast cancer. International Journal of Cancer 119, 2974-2979CrossRef Google Scholar PubMed

43Wilson, B.J. and Giguere, V. (2008) Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway. Molecular Cancer 7, 49CrossRef Google Scholar

44Eeckhoute, J. et al. (2006) A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes and Development 20, 2513-2526CrossRef Google Scholar PubMed

45Su, J.L. et al. (2007) Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. Journal of Biological Chemistry 282, 19385-19398CrossRef Google Scholar PubMed

46Jonckheere, N. et al. (2007) The human mucin MUC4 is transcriptionally regulated by caudal-related homeobox, hepatocyte nuclear factors, forkhead box A, and GATA endodermal transcription factors in epithelial cancer cells. Journal of Biological Chemistry 282, 22638-22650CrossRef Google Scholar

47Gao, N. et al. (2005) Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development 132, 3431-3443CrossRef Google Scholar PubMed

48Korkmaz, K.S. et al. (2000) Full-length cDNA sequence and genomic organization of human NKX3A - alternative forms and regulation by both androgens and estrogens. Gene 260, 25-36CrossRef Google Scholar

49Kusumegi, T. et al. (2004) BMP7/ActRIIB regulates estrogen-dependent apoptosis: new biomarkers for environmental estrogens. Journal of Biochemical and Molecular Toxicology 18, 1-11CrossRef Google Scholar PubMed

50Dong, J.T. (2001) Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer and Metastasis Reviews 20, 173-193CrossRef Google Scholar PubMed

51Holmes, K. et al. (2008) Nkx3–1 and LEF-1 function as transcriptional inhibitors of estrogen receptor activity. Cancer Research 68, 7380-7385CrossRef Google Scholar PubMed

52Gelmann, E.P., Bowen, C. and Bubendorf, L. (2003) Expression of NKX3.1 in normal and malignant tissues. Prostate 55, 111-117CrossRef Google Scholar PubMed

53Pestalozzi, B.C. et al. (2008) Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. Journal of Clinical Oncology 26, 3006-3014CrossRef Google Scholar PubMed

54Habashy, H.O. et al. (2008) Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. European Journal of Cancer 44, 1541-1551CrossRef Google Scholar PubMed

55Bretschneider, N. et al. (2008) Estrogen induces repression of the breast cancer and salivary gland expression gene in an estrogen receptor alpha-dependent manner. Cancer Research 68, 106-114CrossRef Google Scholar

56Frasor, J. et al. (2003) Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144, 4562-4574CrossRef Google Scholar PubMed

57Ben-Porath, I. et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nature Genetics 40, 499-507CrossRef Google Scholar PubMed

58Williamson, E.A. et al. (2006) BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1). Oncogene 25, 1391-1399CrossRef Google Scholar PubMed

59Prall, O.W. et al. (1997) Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. Journal of Biological Chemistry 272, 10882-10894CrossRef Google Scholar PubMed

60Perou, C.M. et al. (2000) Molecular portraits of human breast tumours. Nature 406, 747-752CrossRef Google Scholar PubMed

61Badve, S. and Nakshatri, H. (2009) Oestrogen receptor-positive breast cancer: towards bridging histopathologic and molecular classifications. Journal of Clinical Pathology 62, 6-12CrossRef Google Scholar PubMed

62Carey, L.A. et al. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. The Journal of the American Medical Association 295, 2492-2502CrossRef Google Scholar PubMed

63Thorat, M.A. et al. (2007) FOXA1 expression in breast cancer is associated with Luminal subtype and good prognosis. Journal of Clinical Pathology 61, 327–32CrossRef Google Scholar PubMed

64Yamaguchi, N. et al. (2008) FoxA1 as a lineage-specific oncogene in luminal type breast cancer. Biochemical and Biophysical Research Communications 365, 711-717CrossRef Google Scholar PubMed

65Conlin, A.K. and Seidman, A.D. (2007) Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer. Molecular Diagnosis and Therapy 11, 355-360CrossRef Google Scholar PubMed

66Paik, S. et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Journal of Clinical Oncology 24, 3726-3734CrossRef Google Scholar PubMed

67Bhat-Nakshatri, P. et al. (2008) AKT alters genome-wide estrogen receptor {alpha} binding and impacts estrogen signaling in breast cancer. Molecular and Cellular Biology 28, 7487-7503CrossRef Google Scholar PubMed

68Sayeed, A. et al. (2007) Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Research 67, 7746-7755CrossRef Google Scholar PubMed

69van Agthoven, T. et al. (2008) Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Research and Treatment Mar 21; [Epub ahead of print]Google Scholar PubMed

70Sotiriou, C. et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. Journal of the National Cancer Institute 98, 262-272CrossRef Google Scholar PubMed

71Loi, S. et al. (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. Journal of Clinical Oncology 25, 1239-1246CrossRef Google Scholar PubMed

72Wolf, I. et al. (2007) FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. International Journal of Cancer 120, 1013-1022CrossRef Google Scholar

73Roman, S.D. et al. (1993) Estradiol induction of retinoic acid receptors in human breast cancer cells. Cancer Research 53, 5940-5945Google Scholar PubMed

74Veronesi, U. et al. (2006) Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Annals of Oncology 17, 1065-1071CrossRef Google Scholar PubMed

75Qian, X. et al. (1995) Decreased expression of hepatocyte nuclear factor 3 alpha during the acute-phase response influences transthyretin gene transcription. Molecular and Cellular Biology 15, 1364-1376CrossRef Google Scholar PubMed

Further reading, resources and contacts

The Cancer Trials Support Unit (CTSU) supports a national network of physicians to participate in National Cancer Institute (NCI)-sponsored Phase III clinical trials:

Sotiriou, C. and Piccart, M.J. (2007) Taking gene expression profiling to the clinic; when will molecular signatures become relevant to patient care? Nature Reviews Cancer 7, 545-553CrossRef Google Scholar

Andre, F. and Pusztai, L. (2006) Molecular classification of breast cancer; implications for selection of adjuvant chemotherapy. Nature Clinical Practice Oncology 3, 621-632CrossRef Google Scholar PubMed

http://www.ctsu.org Google Scholar

Crossref Citations

This article has been cited by the following publications. This list is generated based on data provided by Crossref.

Chowbina, Sudhir R Wu, Xiaogang Zhang, Fan Li, Peter M Pandey, Ragini Kasamsetty, Harini N and Chen, Jake Y 2009. HPD: an online integrated human pathway database enabling systems biology studies. BMC Bioinformatics, Vol. 10, Issue. S11,

Sircoulomb, Fabrice Bekhouche, Ismahane Finetti, Pascal Adélaïde, José Hamida, Azza Ben Bonansea, Julien Raynaud, Stéphane Innocenti, Charlène Charafe-Jauffret, Emmanuelle Tarpin, Carole Ayed, Farhat Ben Viens, Patrice Jacquemier, Jocelyne Bertucci, François Birnbaum, Daniel and Chaffanet, Max 2010. Genome profiling of ERBB2-amplified breast cancers. BMC Cancer, Vol. 10, Issue. 1,

Zaret, Kenneth S. and Carroll, Jason S. 2011. Pioneer transcription factors: establishing competence for gene expression. Genes & Development, Vol. 25, Issue. 21, p. 2227.

Sérandour, Aurélien A. Avner, Stéphane Percevault, Frédéric Demay, Florence Bizot, Maud Lucchetti-Miganeh, Céline Barloy-Hubler, Frédérique Brown, Myles Lupien, Mathieu Métivier, Raphaël Salbert, Gilles and Eeckhoute, Jérôme 2011. Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers. Genome Research, Vol. 21, Issue. 4, p. 555.

Kong, Say Li Li, Guoliang Loh, Siang Lin Sung, Wing‐Kin and Liu, Edison T 2011. Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand‐inducible growth state. Molecular Systems Biology, Vol. 7, Issue. 1,

Tran, Linh M Zhang, Bin Zhang, Zhan Zhang, Chunsheng Xie, Tao Lamb, John R Dai, Hongyue Schadt, Eric E and Zhu, Jun 2011. Inferring causal genomic alterations in breast cancer using gene expression data. BMC Systems Biology, Vol. 5, Issue. 1,

Rubel, Cory A. Lanz, Rainer B. Kommagani, Ramakrishna Franco, Heather L. Lydon, John P. and DeMayo, Francesco J. 2012. Research Resource: Genome-Wide Profiling of Progesterone Receptor Binding in the Mouse Uterus. Molecular Endocrinology, Vol. 26, Issue. 8, p. 1428.

Naderi, Ali Meyer, Michelle and Dowhan, Dennis H. 2012. Cross-regulation between FOXA1 and ErbB2 Signaling in Estrogen Receptor-Negative Breast Cancer. Neoplasia, Vol. 14, Issue. 4, p. 283.

Tominaga, N. Naoi, Y. Shimazu, K. Nakayama, T. Maruyama, N. Shimomura, A. Kim, S.J. Tamaki, Y. and Noguchi, S. 2012. Clinicopathological analysis of GATA3-positive breast cancers with special reference to response to neoadjuvant chemotherapy. Annals of Oncology, Vol. 23, Issue. 12, p. 3051.

Guttilla, Irene K. Adams, Brian D. and White, Bruce A. 2012. ERα, microRNAs, and the epithelial–mesenchymal transition in breast cancer. Trends in Endocrinology & Metabolism, Vol. 23, Issue. 2, p. 73.

Haughian, James M. Pinto, Mauricio P. Harrell, J. Chuck Bliesner, Brian S. Joensuu, Kristiina M. Dye, Wendy W. Sartorius, Carol A. Tan, Aik Choon Heikkilä, Päivi Perou, Charles M. and Horwitz, Kathryn B. 2012. Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proceedings of the National Academy of Sciences, Vol. 109, Issue. 8, p. 2742.

Rodríguez-Cruz, Maricela Coral-Vázquez, Ramón M. Hernández-Stengele, Gabriel Sánchez, Raúl Salazar, Emmanuel Sanchez-Muñoz, Fausto Encarnación-Guevara, Sergio and Ramírez-Salcedo, Jorge 2013. Identification of Putative Ortholog Gene Blocks Involved in Gestant and Lactating Mammary Gland Development: A Rodent Cross-Species Microarray Transcriptomics Approach. International Journal of Genomics, Vol. 2013, Issue. , p. 1.

Lindner, Robert Sullivan, Catherine Offor, Onyinye Lezon-Geyda, Kimberly Halligan, Kyle Fischbach, Neal Shah, Mansi Bossuyt, Veerle Schulz, Vincent Tuck, David P. Harris, Lyndsay N. and Miller, Todd W. 2013. Molecular Phenotypes in Triple Negative Breast Cancer from African American Patients Suggest Targets for Therapy. PLoS ONE, Vol. 8, Issue. 11, p. e71915.

Ivanov, S V Panaccione, A Nonaka, D Prasad, M L Boyd, K L Brown, B Guo, Y Sewell, A and Yarbrough, W G 2013. Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas. British Journal of Cancer, Vol. 109, Issue. 2, p. 444.

Wang, Liang Qin, Huaizhou Li, Lihong Feng, Fuqiang Ji, Peigang Zhang, Jingyu Li, Gang Zhao, Zhenwei and Gao, Guodong 2013. Forkhead-box A1 transcription factor is a novel adverse prognosis marker in human glioma. Journal of Clinical Neuroscience, Vol. 20, Issue. 5, p. 654.

Fiorito, Elisa Katika, Madhumohan R. and Hurtado, Antoni 2013. Cooperating transcription factors mediate the function of estrogen receptor. Chromosoma, Vol. 122, Issue. 1-2, p. 1.

van Roon, Eddy H Boot, Arnoud Dihal, Ashwin A Ernst, Robert F van Wezel, Tom Morreau, Hans and Boer, Judith M 2013. BRAF mutation-specific promoter methylation of FOX genes in colorectal cancer. Clinical Epigenetics, Vol. 5, Issue. 1,

Montani, Matteo Herrmanns, Thomas Müntener, Michael Wild, Peter Sulser, Tullio and Kristiansen, Glen 2013. Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression. Virchows Archiv, Vol. 462, Issue. 4, p. 437.

Meyer, Kerstin B. O’Reilly, Martin Michailidou, Kyriaki Carlebur, Saskia Edwards, Stacey L. French, Juliet D. Prathalingham, Radhika Dennis, Joe Bolla, Manjeet K. Wang, Qin de Santiago, Ines Hopper, John L. Tsimiklis, Helen Apicella, Carmel Southey, Melissa C. Schmidt, Marjanka K. Broeks, Annegien Van ’t Veer, Laura J. Hogervorst, Frans B. Muir, Kenneth Lophatananon, Artitaya Stewart-Brown, Sarah Siriwanarangsan, Pornthep Fasching, Peter A. Lux, Michael P. Ekici, Arif B. Beckmann, Matthias W. Peto, Julian dos Santos Silva, Isabel Fletcher, Olivia Johnson, Nichola Sawyer, Elinor J. Tomlinson, Ian Kerin, Michael J. Miller, Nicola Marme, Federick Schneeweiss, Andreas Sohn, Christof Burwinkel, Barbara Guénel, Pascal Truong, Thérèse Laurent-Puig, Pierre Menegaux, Florence Bojesen, Stig E. Nordestgaard, Børge G. Nielsen, Sune F. Flyger, Henrik Milne, Roger L. Zamora, M. Pilar Arias, Jose I. Benitez, Javier Neuhausen, Susan Anton-Culver, Hoda Ziogas, Argyrios Dur, Christina C. Brenner, Hermann Müller, Heiko Arndt, Volker Stegmaier, Christa Meindl, Alfons Schmutzler, Rita K. Engel, Christoph Ditsch, Nina Brauch, Hiltrud Brüning, Thomas Ko, Yon-Dschun Nevanlinna, Heli Muranen, Taru A. Aittomäki, Kristiina Blomqvist, Carl Matsuo, Keitaro Ito, Hidemi Iwata, Hiroji Yatabe, Yasushi Dörk, Thilo Helbig, Sonja Bogdanova, Natalia V. Lindblom, Annika Margolin, Sara Mannermaa, Arto Kataja, Vesa Kosma, Veli-Matti Hartikainen, Jaana M. Chenevix-Trench, Georgia Wu, Anna H. Tseng, Chiu-chen Van Den Berg, David Stram, Daniel O. Lambrechts, Diether Thienpont, Bernard Christiaens, Marie-Rose Smeets, Ann Chang-Claude, Jenny Rudolph, Anja Seibold, Petra Flesch-Janys, Dieter Radice, Paolo Peterlongo, Paolo Bonanni, Bernardo Bernard, Loris Couch, Fergus J. Olson, Janet E. Wang, Xianshu Purrington, Kristen Giles, Graham G. Severi, Gianluca Baglietto, Laura McLean, Catriona Haiman, Christopher A. Henderson, Brian E. Schumacher, Fredrick Le Marchand, Loic Simard, Jacques Goldberg, Mark S. Labrèche, France Dumont, Martine Teo, Soo-Hwang Yip, Cheng-Har Phuah, Sze-Yee Kristensen, Vessela Grenaker Alnæs, Grethe Børresen-Dale, Anne-Lise Zheng, Wei Deming-Halverson, Sandra Shrubsole, Martha Long, Jirong Winqvist, Robert Pylkäs, Katri Jukkola-Vuorinen, Arja Kauppila, Saila Andrulis, Irene L. Knight, Julia A. Glendon, Gord Tchatchou, Sandrine Devilee, Peter Tollenaar, Robert A.E.M. Seynaeve, Caroline M. García-Closas, Montserrat Figueroa, Jonine Chanock, Stephen J. Lissowska, Jolanta Czene, Kamila Darabi, Hartef Eriksson, Kimael Hooning, Maartje J. Martens, John W.M. van den Ouweland, Ans M.W. van Deurzen, Carolien H.M. Hall, Per Li, Jingmei Liu, Jianjun Humphreys, Keith Shu, Xiao-Ou Lu, Wei Gao, Yu-Tang Cai, Hui Cox, Angela Reed, Malcolm W.R. Blot, William Signorello, Lisa B. Cai, Qiuyin Pharoah, Paul D.P. Ghoussaini, Maya Harrington, Patricia Tyrer, Jonathan Kang, Daehee Choi, Ji-Yeob Park, Sue K. Noh, Dong-Young Hartman, Mikael Hui, Miao Lim, Wei-Yen Buhari, Shaik A. Hamann, Ute Försti, Asta Rüdiger, Thomas Ulmer, Hans-Ulrich Jakubowska, Anna Lubinski, Jan Jaworska, Katarzyna Durda, Katarzyna Sangrajrang, Suleeporn Gaborieau, Valerie Brennan, Paul McKay, James Vachon, Celine Slager, Susan Fostira, Florentia Pilarski, Robert Shen, Chen-Yang Hsiung, Chia-Ni Wu, Pei-Ei Hou, Ming-Feng Swerdlow, Anthony Ashworth, Alan Orr, Nick Schoemaker, Minouk J. Ponder, Bruce A.J. Dunning, Alison M. and Easton, Douglas F. 2013. Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. The American Journal of Human Genetics, Vol. 93, Issue. 6, p. 1046.

Liu, Yawei Carlsson, Robert Comabella, Manuel Wang, JunYang Kosicki, Michael Carrion, Belinda Hasan, Maruf Wu, Xudong Montalban, Xavier Dziegiel, Morten Hanefeld Sellebjerg, Finn Sørensen, Per Soelberg Helin, Kristian and Issazadeh-Navikas, Shohreh 2014. FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nature Medicine, Vol. 20, Issue. 3, p. 272.

Download full list

Article contents

FOXA1 in breast cancer

Abstract

Access options

References

References

Further reading, resources and contacts

Save article to Kindle

Save article to Dropbox

Save article to Google Drive

Reply to: Submit a response

Your details

You have entered the maximum number of contributors

Conflicting interests